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ABSTRACT 
 
Patients with bipolar disorder (BD) experience persistent circadian rhythm and sleep 
abnormalities during periods of remission, and biological studies have shown that these 
patients have abnormal melatonin secretion profiles or reactivity to light. We previously 
reported the association with BD of a common polymorphism (rs4446909) of the promoter of 
the acetylserotonin O-methyltransferase (ASMT) gene, encoding one of the two enzymes 
involved in melatonin biosynthesis. This variant was associated with weaker transcription and 
lower levels of ASMT activity in lymphoblastoid cell lines. Actigraphy, based on the use of a 
mobile portable device for the analysis of sleep/wake cycles in natural conditions, may be 
useful for studies of carriers of the at-risk allele. We studied the association between the 
ASMT rs4446909 variant and sleep/activity, as assessed with the Pittsburgh Sleep Quality 
Index (PSQI) and by actigraphy, in 53 subjects (25 patients with BD in remission and 28 
healthy controls). The two groups were similar for age, sex ratio, current mood symptoms, 
body mass index and risk of sleep apnea syndrome. In the total sample, the GG at-risk 
genotype was associated with longer sleep duration (p=0.03), greater activity in active periods 
of sleep (p=0.015) and greater inter-day stability (p=0.003). These associations remained 
significant when disease status was included in the model. Only the association with inter-day 
stability remained significant after correction for multiple testing. This pilot study thus shows 
that a BD-associated functional variant involved in the melatonin synthesis pathway 
influences sleep and circadian rhythms in bipolar patients in remission and controls. 
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Introduction 
Bipolar disorder (BD) is a severe psychiatric disorder characterized by alternating periods of 
elevated mood (manic or hypomanic episodes) and depression, interspaced by periods of 
euthymia. BD affects 1 to 4% of the population worldwide, and has a complex and 
multifactorial etiology, involving genetic and environmental risk factors (Leboyer & Kupfer, 
2010; Geoffroy et al., 2013).  Circadian phenotypes and circadian genes have been widely 
studied in BD, and there is evidence for a deregulation of the circadian rhythm and 
abnormalities of numerous circadian biomarkers in patients, during both acute episodes and 
remission (Etain et al., 2011).  
 
BD patients in clinical remission differ from healthy controls in terms of sleep/wake cycles, 
including phase advance, percentage of nighttime sleep and daytime activity level (McClung, 
2007). Actigraphic assessments have confirmed that patients in remission have more sleep 
abnormalities, spend more time in bed and have a higher frequency of waking shortly after 
sleep onset than controls, with a lower sleep efficiency and greater variability of rhythms 
(Millar et al., 2004; Jones et al., 2005; Harvey et al., 2005; Salvatore et al., 2008; Mullin et 
al., 2011). Biological studies have also revealed numerous abnormalities of circadian rhythms 
in BD patients: core temperature, blood pressure, plasma cortisol, norepinephrine and TSH 
(thyroid-stimulating hormone) concentrations and the rhythmicity of hypothalamic-pituitary 
axis secretion are all affected (Milhiet et al., 2011).  
 
Melatonin is a neurohormone synthesized by the pineal gland from tryptophan, via serotonin. 
Its secretion is synchronized by day/night cycles, and it has both sleep-promoting and 
circadian rhythm-regulating activities (Pandi-Perumal et al., 2006). Patients with BD are 
supersensitive to melatonin suppression by light (Hallam et al., 2006; McIntyre et al., 1989; 
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Nurnberger et al., 1988). This characteristic has been identified as a possible biomarker “trait” 
of BD, independent of the subject's mood states, strongly heritable and increasing with the 
genetic load in a family (Hallam et al., 2006; Pacchierotti et al., 2001). 
 
We have recently demonstrated an association between BD and genetic variants of the 
acetylserotonin O-methyltransferase gene (ASMT, OMIM 300015/402500) encoding the 
enzyme responsible for the final step of melatonin biosynthesis (Etain et al., 2012). We first 
identified several rare deleterious ASMT mutations in patients, and showed that these 
mutations were associated with low levels of ASMT activity in B-lymphoblastoid cell lines 
(BLCLs). We then showed that the level of ASMT activity was generally lower in patient 
than in control BLCL. We showed that rs4446909, a common variant of the ASMT promoter 
region, was significantly associated with BD, and with lower transcript abundance and lower 
levels of enzymatic activity, providing a partial explanation for the lower than normal levels 
of ASMT activity in patients (Etain et al., 2012).  
 
We report here further characterization of the phenotypic expression of the rs4446909 
susceptibility allele. We studied sleep/activity patterns for patients with BD and healthy 
controls, on the basis of actigraphy and sleep quality self-reports. 
 
Materials and methods 
 
Population 
Fifty-three Caucasian adult subjects (25 euthymic patients with BD in remission and 28 
healthy subjects) were included in the study at our university-affiliated psychiatric department 
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(Paris Est University). Written informed consent was obtained from all participants. 
Institutional review board approval was obtained for this study.  
 
For inclusion in the study, patients had to be (i) diagnosed with bipolar disorder (type I, II or 
NOS), according to DSM-IV criteria (American Psychiatric Association, 2000), (ii) euthymic, 
with both a Montgomery–Asberg Depression Rating Scale (MADRS) score (Montgomery & 
Asberg, 1979) and a Young Manic rating scale (YMRS) (Young et al., 1978) of no more than 
seven (according to ISBD task force criteria for symptomatic remission (Tohen et al., 2009)) 
and (iii) in remission, defined as the absence of mood episodes during a period three months 
immediately preceding participation in the study. Patients were interviewed with the French 
version of the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al., 1994), 
which provides lifetime DSM-IV axis I diagnoses.   
 
The unaffected control group was recruited from blood donors attending Henri Mondor 
Hospital (a general hospital in Paris, France). Unaffected controls were assessed with the 
DIGS and assessed for family history of psychiatric disorders with the Family Interview for 
Genetic Studies (FIGS) (Maxwell, 1992). Only subjects with no personal or family history of 
affective disorders or suicide attempts were included.  
 
Patients and controls were excluded if they presented any of the following during the three 
months preceding the study: i) severe insomnia, ii) psychostimulant drug use, iii) 
psychotropic treatment modification or initiation, iv) hospitalization, v) electro-convulsive 
therapy, or vi) any life event likely to have an effect on sleep patterns (including, for example, 
shift work, travel with more than three hours of jet lag, pregnancy, child birth, grief, trauma, 
or somatic disease with associated sleep disturbances). 
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Assessment procedures 
All participants were assessed for a period of 21 consecutive days, with a subjective measure 
of sleep, the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989), and an objective 
measure of sleep, actigraphy.  
 
We used the total score of the PSQI, which is a 19-item self-completed questionnaire 
requiring the participant to describe patterns of sleep, such as typical bedtime and wake time, 
sleep latency and actual sleep time (Buysse et al., 1989). The patient is also asked about 
sleeping habits and quality. The French version of this questionnaire has been validated (Blais 
et al., 1997). 
 
The American Academy of Sleep Medicine considers actigraphy to be the most relevant non-
invasive method for assessing sleep/wake irregularities (Morgenthaler et al., 2007). All 
participants continuously wore an actigraph (AW-7 CamNtech) on the wrist of the non-
dominant hand, making it possible to collect at least 21 consecutive cycles, with each cycle 
corresponding to 24 hours. The AW-7 actigraph consists of an accelerometer that detects the 
intensity and amount of movement as a function of time. For this study, a time of 1 minute per 
epoch and an “average” sensitivity threshold were chosen by default. Instructions were kept to 
a minimum, to try to guarantee that the study was naturalistic and did not intrude on routine 
sleep/activity measurements. Participants were instructed to press the actiwatch event marker 
when they went to bed at night (to go to sleep) and again when they got up (to start the next 
day); they were also asked to complete a sleep diary. In addition, as this study focused on 
routine sleep-wake cycles, we avoided the recording of data when participants were on 
vacation or involved in unusual periods of activity. 
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Two experienced psychiatrists (CB and PAG) analyzed the actigraphic records of the two 
groups. Markers reported by the patient by the pressing of the actigraph button at bedtime and 
on getting up were used for signal analysis. The sleep diary completed by the participant for 
the duration of the recording period was used to correct missing and/or outlier markers. 
Subsequently, the automatic algorithm program (Actiwatch Activity & Sleep Analysis Ltd 
CamNtech 7.28) was applied to all records, to calculate the various actimetric measurements 
of sleep and activity. Finally, visual inspection by a trained observer (PAG or CB) was used 
to correct incongruences between the definition, by the algorithm, of a rest interval and the 
schedules provided by the participant’s marker recordings and the sleep diary (Boudebesse et 
al., 2012). 
 
Genotyping 
Genomic DNA was isolated from blood lymphocytes or B-lymphoblastoid cell lines from 
independent cases and controls, with the Nucleon BACC3 kit (GE HealthCare, Chalfont St 
Giles, UK). The ASMT promoter, containing rs4446909, was amplified by polymerase chain 
reaction (PCR) methods, as previously described (Etain et al., 2012). The sequence of the 
ASMT promoter was analyzed by direct sequencing of the PCR products, with the BigDye® 
Terminator v3.1 cycle sequencing kit and a 16-capillary ABI PRISM® 3130xl Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). 
 
Statistics 
All analyses were performed with SPSS 19.0.  
Non-parametric tests (the Mann-Whitney test for continuous variables and the Chi2 test for 
categorical variables) were used to compare patients and controls for potential confounding 
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factors, such as sex, age, mood state (MADRS, YMRS), body mass index (BMI) and risk of 
sleep apnea syndrome (SAS) (assessed with the Berlin Questionnaire (Netzer et al., 1999)).  
 
We explored the association between the rs4446909 genotypes and actigraphic measures, by 
pooling patients and control subjects. Individuals with the AA and AG genotypes were pooled 
into a single category and compared with those with the GG genotype (recessive model for 
the G, at-risk allele). There were two reasons for this approach. First, the AA genotype is 
infrequent and our sample size was such that it could not be analyzed as a single category in 
this study. Second, the GG genotype is associated with lower than normal levels of ASMT 
enzymatic activity, consistent with G being a recessive allele (Etain et al., 2012). Hardy–
Weinberg equilibrium was assessed for rs4446909 in our population. 
 
A one-way between-subjects analysis of covariance (ANCOVA) was used to assess the effect 
of genotype on dependent actigraphic measures, with bipolar/healthy status used as a 
covariate. The homogeneity of regression and the linear relationship between covariates and 
the dependent variable were tested and confirmed. We decreased the number of statistical 
tests required, by focusing on eight candidate actigraphic measurements: four for sleep (sleep 
duration, sleep latency, sleep efficiency, mean activity in active periods), two for phase (L5 
onset, M10 onset), one for stability (inter-day stability) and one for amplitude (amplitude). 
Other actigraphic measures (time in bed, relative amplitude, intra-day variability, WASO, 
fragmentation index) were not investigated, as they were strongly correlated with the selected 
measurements. Assuming that eight independent tests were carried out, we applied Bonferroni 
correction for multiple testing (0.05/8 = 0.00625). 
 
Results 
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Fifty-three subjects were included in the study: 25 patients with BD in remission, and 28 
unaffected individuals.  
 
The two groups were similar in terms of age, sex-ratio, YMRS score, BMI and SAS risk 
(table 1). MADRS scores differed significantly between patients and controls (p=0.009), but 
the means were very low for both groups, corresponding to a clinical absence of depressive 
symptoms. We therefore included no covariates in the models. 
 
The GG genotype was found in 11 of the 25 subjects with BD and 12 of the 28 healthy 
subjects (total n=23). The AA genotype was found in 4 of the 25 subjects with BD and 2 of 
the 28 healthy subjects, whereas the AG genotype was found in 10 of the 25 subjects with BD 
and 14 of the 28 healthy subjects (giving a total n for these two genotypes of 30: 14 subjects 
with BD and 16 healthy subjects). The rs4446909 genotype distribution was in Hardy–
Weinberg equilibrium (p=0.94) and did not differ between the two groups (pexact=0.64).  
 
No association was observed between rs4446909 genotype and sleep quality, as measured by 
PSQI total score (U=378, p=0.37).  
 
For the pooled samples of patients and controls, univariate analyses showed an association 
between the GG at-risk genotype and each of the following variables: longer sleep duration 
(p=0.03), greater activity during active periods of the night (p=0.015) and a higher inter-day 
stability (p=0.003). Sleep latency, sleep efficiency, L5 onset, M10 onset and amplitude did 
not differ between the rs4446909 genotype groups (table 2). Only the association with inter-
day stability remained significant after correction for multiple testing. 
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Multivariate analyses including disease status (first column) as a covariate confirmed the 
association between the GG genotype and the three actigraphic measurements (table 2). The 
disease model (second column of multivariate analyses) showed a main effect of disease 
status (BD case versus control) on the actigraphic variables. These results confirm that, for 
two of the three actigraphic measurements (for sleep duration and inter-day stability, but not 
for mean activity in active periods) the observed effect of the ASMT gene variant on the 
actigraphic variables is not associated with disease status (table 2). 
 
Discussion 
This is the first study investigating the relationship between a functional variant involved in 
the melatonin synthesis pathway and sleep/wake patterns in a sample of bipolar patients in 
remission and healthy controls. The GG at-risk genotype at rs4446909 in the promoter of the 
ASMT gene is associated with susceptibility to BD and a lower than level of enzymatic 
activity for the corresponding protein (Etain et al., 2012). We show here that this genotype is 
also associated with a longer sleep duration and higher levels of activity during active periods 
of sleep, both consistent with a worse-than-normal objective sleep quality. These results are 
consistent with the previous finding that these circadian characteristics are associated with BD 
(McClung, 2007; Harvey et al., 2005; Millar et al., 2004). Longer periods of poorer quality 
sleep in BD patients have been repeatedly reported in actigraphic studies (Jones et al., 2005; 
Millar et al., 2004; Mullin et al., 2011; Harvey et al., 2005; Salvatore et al., 2008). ASMT 
may regulate the amplitude of melatonin secretion (Etain et al., 2012) and, consequently, a 
genetic variant associated with a lower level of enzyme activity may influence actigraphic 
sleep amplitude-related variables, causing longer sleep duration and shallower sleep.  
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Melatonin is a synchronizer with several systemic functions, including promoting sleep and 
its quality by causing drowsiness and lowering body temperature (Srinivasan et al., 2006).  
The association between the GG at-risk genotype for BD and better inter-day stability was 
therefore the opposite of what would have been expected. Indeed, inter-day stability in BD 
patients in remission has been shown in previous studies to be lower than normal, with, for 
example, the Social Rhythm Metric (Ashman et al., 1999; Jones et al., 2005)  and actigraphic 
studies (Millar et al., 2004; Salvatore et al., 2008; Jones et al., 2005). Our findings suggest 
that rs4446909 does not itself cause rhythm irregularities. Other variants of this gene or of 
other genes may be involved in these irregularities (Relógio et al., 2011; Hastings et al., 
2007). The phase of melatonin secretion is regulated more strongly by aralkylamine N-
acetyltransferase (AANAT) than by ASMT and the stability of circadian rhythms appears to 
involve the ROR/Bmal/REV-ERB (RBR) loop. Consequently, genes encoding AANAT or the 
RBR loop may contribute to inter-day stability and instability. Investigations of the entire 
melatonin pathway and of other circadian genes may explain these preliminary results and 
disentangle the circadian physiology responsible for the instability of the sleep/wake cycle in 
BD patients.   
 
In our sample, the common variant of the ASMT promoter associated with BD was not 
associated with subjective sleep quality. This absence of association may reflect the small 
sample size or the commonly observed discrepancy between subjective assessments and 
objective actigraphic sleep measurements in patients with BD (Harvey et al., 2005). In the 
study by Harvey et al., euthymic patients overestimated their sleep latency and 
underestimated their sleep duration (Harvey et al., 2005). Observations are similar for patients 
with insomnia, who misperceive their sleep characteristics, by overestimating waking during 
sleep, for example (Mercer et al., 2002).  
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The inclusion of both euthymic BD patients and control subjects in the study group is one of 
the strengths of our study, also revealing an influence of the variant studied on actigraphic 
measurements in the general population. Of particular interest, this variant is associated with 
both the disorder (Etain et al., 2012) and with actigraphic markers that appear to be trait 
markers of BD (Milhiet et al., 2011). 
 
This study has several limitations. First, the sample was small (53 subjects), although of a 
reasonable size for an actigraphic study (Millar et al., 2004; Jones et al., 2005; Harvey et al., 
2005; Salvatore et al., 2008; Mullin et al., 2011).  A larger sample would increase the power 
for detecting small effects and should probably be recommended for future studies combining 
actigraphic and genetic data. However, this study was not based on genetic and phenotypic 
screening (which would have increased the risk of type I errors). Our strategy was hypothesis-
driven and based on a specific aim. The ASMT promoter gene variant is a good candidate for 
association with circadian phenotypes, hence the design of this study. This so-called “reverse 
phenotyping” strategy is a recognized and increasingly common approach to evaluating the 
biological significance of signals obtained in genetic association studies (Arif et al., 2013). 
We also carried out a post-hoc calculation of power. The multivariate analyses demonstrated 
adequate power in all instances (e.g. 78% power to detect between-group differences for 
activity (for genes and disease status, controlling for age and sex), with an effect size of 0.36 
for the model). Both the power and effect sizes are estimated post-hoc, but we consider them 
to be reasonable and they suggest that our results are reliable and potentially valid. As the 
primary goal of our work was to demonstrate a feasible new method for assessing the 
associations between sleep parameters and circadian genes, we feel that this study constitutes 
an important first step in this direction. 
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We did not control for psychotropic medication or for professional status, both of which are 
possible confounding factors, in this study. However, the type and dose of psychotropic 
medication were previously found to be unrelated to actigraphic measurements in similar 
patients with BD in remission (Salvatore et al., 2008). In addition, the associations between 
rs4446909 and actigraphic measurements remained significant in the multivariate analyses 
including disease status as a covariable. We therefore think that it is unlikely that 
psychotropic drugs or professional status would have a major influence. 
 
Finally, as supersensitivity to melatonin suppression by light has been demonstrated only for 
patients with BD and patients with seasonal affective disorder (SAD), but not in patients with 
major depressive disorder (MDD), it might be advisable for future studies to include only 
patients with BD subtype I or at least with seasonal patterns of mood episodes (McIntyre et 
al., 1989; Nathan et al., 1999). 
 
If confirmed, these results have various implications. Theoretically, sleep disturbances in 
patients with BD in remission could be treated by manipulating the circadian system with 
chronobiotic drugs (e.g. melatonin), chronotherapeutics (e.g. bright light therapy or sleep 
deprivation) or psychological interventions focusing on rhythms and sleep (Livianos et al., 
2012; Pacchierotti et al., 2001; Wu et al., 2009; Benedetti et al., 2005a; St-Amand et al., 
2012). Patients carrying this at-risk genotype might show different patterns of therapeutic 
response to treatments of this type acting directly on the circadian system or, more generally, 
to treatments involving mood stabilizers. Indeed, it has been suggested that circadian genes 
may modulate the therapeutic response to mood stabilizers (Benedetti et al., 2004, 2005b). 
These findings contribute to our understanding of the circadian pathophysiology of BD and its 
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complex multifactorial heritability. They also indicate a new area for research to identify 
treatment targets. 
 
Conclusion 
We report here, for a sample of patients with BD in remission and healthy subjects, an 
association between a BD susceptibility allele (ASMT rs4446909) and sleep/activity patterns, 
as assessed by actigraphy. This reverse phenotyping approach helps shed light on the 
mechanisms associated with sleep disturbances and circadian rhythm instability, both frequent 
in patients with BD in remission. These findings also suggest new avenues of research for 
elucidating the complex interactions between the biology of circadian rhythms and 
susceptibility to BD. Our preliminary results require confirmation in independent samples of 
patients with BD and of patients with other disorders, such as recurrent depression or 
insomnia. 
 
References 
American Psychiatric Association. (2000) Diagnostic and Statistical Manual of Mental 
Disorders DSM-IV-TR Fourth Edition. (4th ed.), American Psychiatric Publishing, Arlington. 
Arif, B., Kumar, K. R., Seibler, P., Vulinovic, F., Fatima, A., Winkler, S., Nürnberg, G., 
Thiele, H., Nürnberg, P., Jamil, A. Z., Brüggemann, A., Abbas, G., Klein, C., Naz, S. & 
Lohmann, K. (2013) A novel OPA3 mutation revealed by exome sequencing: an example of 
reverse phenotyping. JAMA Neurol 70, 783–787. 
Ashman, S. B., Monk, T. H., Kupfer, D. J., Clark, C. H., Myers, F. S., Frank, E. & Leibenluft 
(1999) Relationship between social rhythms and mood in patients with rapid cycling bipolar 
disorder. Psychiatry Res 86, 1–8. 
Benedetti, F., Barbini, B., Fulgosi, M. C., Colombo, C., Dallaspezia, S., Pontiggia, A. & 
Smeraldi, E. (2005a) Combined total sleep deprivation and light therapy in the treatment of 
drug-resistant bipolar depression: acute response and long-term remission rates. J Clin 
Psychiatry 66, 1535–1540. 
Benedetti, F., Serretti, A., Colombo, C., Lorenzi, C., Tubazio, V. & Smeraldi, E. (2004) A 
glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated 
with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 
368, 123–126. 
 15 
Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C. & 
Smeraldi, E. (2005b) Long-term response to lithium salts in bipolar illness is influenced by 
the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376, 51–55. 
Blais, F. C., Gendron, L., Mimeault, V., and Morin, C. M. (1997) [Evaluation of insomnia: 
validity of 3 questionnaires]. Encephale 23, 447–453. 
Boudebesse, C., Leboyer, M., Begley, A., Wood, A., Miewald, J., Hall, M., Frank, E., Kupfer, 
D. & Germain, A. (2012). Comparison of five actigraphy scoring methods with bipolar 
disorder. Behav Sleep Med 11, 275-282. 
Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R. & Kupfer, D. J. (1989) The 
Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. 
Psychiatry Res 28, 193–213. 
Etain, B., Dumaine, A., Bellivier, F., Pagan, C., Francelle, L., Goubran-Botros, H., Moreno, 
S., Deshommes, J., Moustafa, K., Le Dudal, K., Mathieu, F., Henry, C., Kahn, J.P., Launay, 
J.M., Mühleisen, T.W., Cichon, S., Bourgeron, T., Leboyer, M. & Jamain, S. (2012) Genetic 
and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar 
disorder. Hum Mol Genet 21, 4030-4037. 
Etain, B., Milhiet, V., Bellivier, F. & Leboyer, M. (2011) Genetics of circadian rhythms and 
mood spectrum disorders. Eur Neuropsychopharmacol J 21 Suppl 4, S676–682. 
Geoffroy, P. A., Etain, B., Scott, J., Henry, C., Jamain, S., Leboyer, M. & Bellivier, F. (2013) 
Reconsideration of bipolar disorder as a developmental disorder: Importance of the time of 
onset. J Physiol Paris 107, 278-285. 
Hallam, K. T., Olver, J. S., Chambers, V., Begg, D. P., McGrath, C. & Norman, T. R. (2006) 
The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. 
Psychoneuroendocrinology 31, 867–875. 
Harvey, A. G., Schmidt, D. A., Scarnà, A., Semler, C. N. & Goodwin, G. M. (2005) Sleep-
related functioning in euthymic patients with bipolar disorder, patients with insomnia, and 
subjects without sleep problems. Am J Psychiatry 162, 50–57. 
Hastings, M., O’Neill, J. S. & Maywood, E. S. (2007) Circadian clocks: regulators of 
endocrine and metabolic rhythms. J Endocrinol 195, 187–198. 
Jones, S. H., Hare, D. J. & Evershed, K. (2005) Actigraphic assessment of circadian activity 
and sleep patterns in bipolar disorder. Bipolar Disord 7, 176–186. 
Leboyer, M. & Kupfer, D. J. (2010) Bipolar disorder: new perspectives in health care and 
prevention. J Clin Psychiatry 71, 1689–1695. 
Livianos, L., Sierra, P., Arques, S., García, A. & Rojo, L. (2012) Is melatonin an adjunctive 
stabilizer? Psychiatry Clin Neurosci 66, 82–83. 
Maxwell, M. (1992) Family Interview for Genetic Studies. Clin. Neurogenetics Branch 
Intramural Res. Program NIMH. 
McClung, C. A. (2007) Circadian genes, rhythms and the biology of mood disorders. 
 16 
Pharmacol Ther 114, 222–232. 
McIntyre, I. M., Norman, T. R., Burrows, G. D. & Armstrong, S. M. (1989) Human 
melatonin suppression by light is intensity dependent. J Pineal Res 6, 149–156. 
Mercer, J. D., Bootzin, R. R. & Lack, L. C. (2002) Insomniacs’ perception of wake instead of 
sleep. Sleep 25, 564–571. 
Milhiet, V., Etain, B., Boudebesse, C. & Bellivier, F. (2011) Circadian biomarkers, circadian 
genes and bipolar disorders. J Physiol Paris 105, 183-189. 
Millar, A., Espie, C. A. & Scott, J. (2004) The sleep of remitted bipolar outpatients: a 
controlled naturalistic study using actigraphy. J Affect Disord 80, 145–153. 
Montgomery, S. A. & Asberg, M. (1979) A new depression scale designed to be sensitive to 
change. Br J Psychiatry 134, 382–389. 
Morgenthaler, T., Alessi, C., Friedman, L., Owens, J., Kapur, V., Boehlecke, B., Brown, T., 
Chesson, A., Jr, Coleman, J., Lee-Chiong, T., Pancer, J. & Swick, T.J. (2007) Practice 
parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update 
for 2007. Sleep 30, 519–529. 
Mullin, B. C., Harvey, A. G. & Hinshaw, S. P. (2011) A preliminary study of sleep in 
adolescents with bipolar disorder, ADHD, and non-patient controls. Bipolar Disord 13, 425–
432. 
Nathan, P. J., Burrows, G. D. & Norman, T. R. (1999) Melatonin sensitivity to dim white 
light in affective disorders. Neuropsychopharmacol 21, 408–413. 
Netzer, N. C., Stoohs, R. A., Netzer, C. M., Clark, K. & Strohl, K. P. (1999) Using the Berlin 
Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 131, 
485–491. 
Nurnberger, J. I., Jr, Blehar, M. C., Kaufmann, C. A., York-Cooler, C., Simpson, S. G., 
Harkavy-Friedman, J., Severe, J. B., Malaspina, D. & Reich, T. (1994) Diagnostic interview 
for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch 
Gen Psychiatry 51, 849–859. 
 
Nurnberger, J. I., Jr, Berrettini, W., Tamarkin, L., Hamovit, J., Norton, J. & Gershon, E. 
(1988) Supersensitivity to melatonin suppression by light in young people at high risk for 
affective disorder. A preliminary report. Neuropsychopharmacol 1, 217–223. 
Pacchierotti, C., Iapichino, S., Bossini, L., Pieraccini, F. & Castrogiovanni, P. (2001) 
Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. 
Front Neuroendocrinol 22, 18–32. 
Pandi-Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B. & 
Hardeland, R. (2006) Melatonin: Nature’s most versatile biological signal? FEBS J 273, 
2813–2838. 
Relógio, A., Westermark, P. O., Wallach, T., Schellenberg, K., Kramer, A. & Herzel, H. 
(2011) Tuning the mammalian circadian clock: robust synergy of two loops. PLoS Comput 
 17 
Biol 7, e1002309. 
Salvatore, P., Ghidini, S., Zita, G., De Panfilis, C., Lambertino, S., Maggini, C. & 
Baldessarini, R. J. (2008) Circadian activity rhythm abnormalities in ill and recovered bipolar 
I disorder patients. Bipolar Disord 10, 256–265. 
Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., 
Parry, B. & Cardinali, D. P. (2006) Melatonin in mood disorders. Biol Psychiatry 7, 138–151. 
St-Amand, J., Provencher, M. D., Bélanger, L. & Morin, C. M. (2012) Sleep disturbances in 
bipolar disorder during remission. J Affect Disord 146, 112-119. 
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., 
Calabrese, J. R., Nolen, W. A., Vieta, E., Kapczinski, F., Goodwin, G.M., Suppes, T., Sachs, 
G.S., Chengappa, K.R., Grunze, H., Mitchell, P.B., Kanba, S. & Berk, M. (2009) The 
International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of 
course and outcome in bipolar disorders. Bipolar Disord 11, 453–473. 
Wu, J. C., Kelsoe, J. R., Schachat, C., Bunney, B. G., DeModena, A., Golshan, S., Gillin, J. 
C., Potkin, S. G. & Bunney, W. E. (2009) Rapid and sustained antidepressant response with 
sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 66, 298–301. 
Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. (1978) A rating scale for mania: 
reliability, validity and sensitivity. Br J Psychiatry 133, 429–435. 
 
Acknowledgments 
Funding 
This work was supported by INSERM (Institut National de la Santé et de la Recherche 
Médicale), AP-HP (Assistance Publique des Hôpitaux de Paris), the FondaMental (RTRS 
Santé Mentale) Foundation and the Investissements d'Avenir program managed by the ANR 
under reference ANR-11-IDEX-0004-02. This work was supported by Laboratoires Servier 
(funding for the purchase of actiwatches and for sequence analyses). Laboratoires Servier was 
not involved in the design of the protocol, or the acquisition, analysis and interpretation of 
data.  
Acknowledgments 
We thank the patients with BD and the controls who agreed to participate in this study. We 
thank the staff at the inclusion sites at Paris-Créteil (E. Abadie, A. Raust and B. Cochet for 
 18 
active participation in the clinical assessment). We thank the Clinical Investigation Centre (O. 
Montagne and P. Le Corvoisier), the Biological Resource Centre of Mondor Hospital (B 
Ghaleh), and the cell bank of Cochin Hospital (J Chelly) for biological sample preparation. 
We thank JR Richard, L Ouvrard and N Bord for their assistance. We thank Laboratoires 
Servier. We thank Prof. Jan Scott for her helpful comments on this manuscript. 
 
Conflicts of interest 
PA Geoffroy received a prize from Bayer whilst at the Faculty of Medicine of Lille. 
C. Boudebesse received a research grant from Laboratoires Servier, a prize for her thesis in 
medicine from Sanofi-Aventis, and honoraria as an independent symposium speaker from 
Ostuka. 
B. Etain and F. Bellivier have received honoraria and financial compensation as independent 
symposium speakers from Sanofi-Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol-Myers 
Squibb and Servier.  
C. Henry has received honoraria and financial compensation as an independent symposium 
speaker from Sanofi-Aventis, Lundbeck, AstraZeneca, Eli Lilly, and Bristol-Myers Squibb.  
M. Leboyer has received honoraria and financial compensation as an independent symposium 
speaker from AstraZeneca and Servier.  
A. Henrion and S. Jamain have no conflict of interest to declare.  
 
Authors’ contributions 
Dr PA Geoffroy, Dr C Boudebesse, Ms A Henrion, Dr S Jamain, Prof. C Henry, Prof. M 
Leboyer, Prof. F Bellivier and Dr B Etain contributed to and have approved the submitted 
draft of the paper. FB & BE are the principal investigators of the study. PAG, CB, FB & BE 
designed the study. PAG & CB assessed the bipolar and control subjects. PAG & CB 
performed the actigraphy analyses. AH & SJ performed the genotyping. PAG & BE 
performed the statistical analyses. PAG, CB, AH, SJ, CH, ML, FB & BE contributed to 
interpreting the results and writing the manuscript, and have approved its final version. 
 19 
Table 1: Description of the samples of patients with BD and unaffected controls   
 
Patients with BD 
(n=25) 
n (%) or mean (±SD) 
Controls 
(n=28) 
n (%) or mean (±SD) 
Chi2 or  
Mann Whitney 
p 
Sex: women / men 17 (68%) / 8 (32%) 12 (43%) / 16 (57%) 3.37 0.07 
Age (years)  53.20 (±11.62) 53.93 (±9.23)  331 0.74 
MADRS 1.92 (±2.83)  0.43 (±1.35)  475.5 0.009 
YMRS 0.68 (±1.41) 0.14 (±0.45) 402.5 0.15 
BMI 26.89 (±5.79) 26.55 (±4.22)  340.5 0.87 
SAS Risk: High / Low 6 (24%) / 19 (76%) 2 (7%) / 26 (93%) 2.93 0.09 
BMI= body mass index, MADRS= Montgomery–Asberg Depression Rating Scale, NS= not significant, SAS= sleep apnea 
syndrome, YMRS= Young Manic Rating Scale, BD= bipolar disorder. 
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Table 2:  
Association between rs4446909 and actigraphic variables, as identified by univariate and 
multivariate (covariation with disease status) analyses 
 
Actimetric 
measurements 
Mean (±SD) 
UNIVARIATE ANALYSES 
MULTIVARIATE ANALYSES 
(ANCOVA) 
AA /AG 
genotype 
(n=30) 
GG 
genotype 
(n=23) 
U p 
Genotype 
P value (F) 
Disease 
status* 
P value (F) 
Mean activity in 
active periods 
93.57 
(±29,3) 
115.09 
(±36,3) 
480 0.015 
0.012 
(6.725) 
0.004 
(9.371) 
Sleep duration 
(min) 
452.23 
(±53.3) 
484.17 
(±65.3) 
463 0.03 
0.04 
(4.262) 
0.14 
(2.334) 
Inter-day stability 0.47 (±0.12) 0.57 (±0.12) 508 
0.003*
* 
0.007 
(8.046) 
0.77 
(0.083) 
Sleep latency (min) 
22.47 
(±31.7) 
12.30 (±8.9) 279 0.24   
Sleep efficiency (%) 
 82.37 
(±9.9) 
84.39 (±5.9) 
352
.5 
0.89 
 
 
L5 onset (H:min) 
00:40 
(±01:36) 
00:49 
(±00:59) 
321 0.65   
M10 onset (H:min) 
08:50 
(±02:02) 
08:18 
(±01:00) 
298 0.39 
 
 
Amplitude 
15253.13 
(±4393.1) 
16424.83 
(±3949.2) 
402 0.31 
 
 
*Main effect 
** Significant after correction for multiple testing 
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Table S1: Genotype distribution in subjects with bipolar disorder (BD) and healthy controls  
 
Gene  
(SNP) 
Genotype 
Controls 
(n=28) 
Patients with 
BD (n=25) 
Pooled 
genotypes 
Total sample 
(n=53) 
ASMT  
(rs4446909) 
AA 2 4 
AA and AG 30 
AG 14 10 
GG 12 11 GG 23 
 
 
